Results 51 to 60 of about 12,300 (184)

Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases

BMEMat, EarlyView.
This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou, Jia Liu, Shulin Lai, Suhan Yin, Bingmin Luo, Longquan Shao, Yiyuan Kang   +6 more
wiley   +1 more source

Multiplication of theSNCAlocus exacerbates neuronal nuclear aging [PDF]

Human Molecular Genetics, 2018
Human-induced Pluripotent Stem Cell (hiPSC)-derived models have advanced the study of neurodegenerative diseases, including Parkinson's disease (PD). While age is the strongest risk factor for these disorders, hiPSC-derived models represent rejuvenated neurons. We developed hiPSC-derived Aged dopaminergic and cholinergic neurons to model PD and related
Lidia, Tagliafierro, Madison Elena, Zamora, Ornit, Chiba-Falek   +2 more
openaire   +2 more sources

Evaluating Transcriptomic Biomarkers for rHuEPO Detection: Assessing the Impact of Exercise and Altitude Exposure

Drug Testing and Analysis, EarlyView.
A two‐stage transcriptomic filter comparing rHuEPO, exercise and altitude responses reduced 153 candidate genes to 50 that were unaffected by physiological stimuli. These retained transcripts offer focused biomarker leads to strengthen antidoping detection of rHuEPO.
Daria Obratov, Shaun Sutehall, Longhua Liu, Zhao Zhongying, Yannis Pitsiladis   +4 more
wiley   +1 more source

SNCA overexpression disturbs hippocampal gene expression trajectories in midlife

Aging, 2018
Synucleinopathies like Parkinson's disease and dementia with Lewy bodies originate from a complex and still largely enigmatic interplay of genetic predisposition, age, and environmental factors. While progressively declining motor functions hallmark late-life symptoms, first signs of the disease often surface already decades earlier during midlife.
Hentrich, Thomas, Wassouf, Zinah, Riess, Olaf, Schulze-Hentrich, Julia M.   +3 more
openaire   +2 more sources

Motor and Cognitive Outcome After Subthalamic Nucleus Deep Brain Stimulation in Patients with Parkinson's Disease Harboring GBA1 Variant

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Deep brain stimulation (DBS) is effective for Parkinson's disease (PD); however, its efficacy varies with genetic background, such as the GBA1 variant—the causative gene of Gaucher disease—associated with increased PD risk and cognitive decline after subthalamic nucleus (STN)‐DBS.
Hikaru Kamo, Genko Oyama, Mai Shimizu, Haruka Takeshige‐Amano, Takashi Ogawa, Wataru Sako, Noriko Nishikawa, Taku Hatano, Yuanzhe Li, Hiroyo Yoshino, Manabu Funayama, Masanobu Ito, Hirokazu Iwamuro, Atsushi Umemura, Nobutaka Hattori   +14 more
wiley   +1 more source

Reducing effect of insulin resistance on alpha-synuclein gene expression in skeletal muscle

Diabetology & Metabolic Syndrome, 2019
Background Alpha-synuclein (SNCA) as the presynaptic protein is expressed in different tissues and prevents insulin-resistance (IR) through increasing glucose-uptake by adipocytes and muscles.
Amirhosein Khoshi, Golnaz Goodarzi, Rezvan Mohammadi, Roghaye Arezumand, Meysam Moghbeli, Mahnaz Najariyan   +5 more
doaj   +1 more source

Discovery of functional non-coding conserved regions in the α-synuclein gene locus [v2; ref status: indexed, http://f1000r.es/4v9]

F1000Research, 2014
Several single nucleotide polymorphisms (SNPs) and the Rep-1 microsatellite marker of the α-synuclein ( SNCA) gene have consistently been shown to be associated with Parkinson’s disease, but the functional relevance is unclear. Based on these findings we
Lori Sterling, Michael Walter, Dennis Ting, Birgitt Schüle   +3 more
doaj   +1 more source

Targeted attenuation of elevated histone marks at SNCA alleviates α‐synuclein in Parkinson's disease

EMBO Molecular Medicine, 2021
Epigenetic deregulation of α‐synuclein plays a key role in Parkinson’s disease (PD). Analysis of the SNCA promoter using the ENCODE database revealed the presence of important histone post‐translational modifications (PTMs) including transcription ...
Subhrangshu Guhathakurta, Jinil Kim, Levi Adams, Sambuddha Basu, Min Kyung Song, Evan Adler, Goun Je, Mariana Bernardo Fiadeiro, Yoon‐Seong Kim   +8 more
doaj   +1 more source

Alzheimer's Biomarkers and Visuospatial Cognition in Parkinson's Disease: Modification by α‐Synuclein and Mediation of Age Effects

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Visuospatial deficits in Parkinson's disease (PD) often precede dementia and complicate daily functioning. Alzheimer's disease (AD) pathology and α‐synuclein aggregation frequently co‐occur in PD, but their combined impact on cognition is unclear.
David Ledingham, Sahana Sathyanarayana, Charlotte B. Stewart, Robyn Iredale, Victoria Foster, Debra Galley, Meher Lad, Mark R. Baker, Nicola Pavese   +8 more
wiley   +1 more source

Focused Ultrasound for the Treatment of Circuit and Molecular Pathology in Parkinson's Disease

Movement Disorders, EarlyView.
Abstract Focused ultrasound is rapidly emerging as a novel technology for the development of symptomatic therapies and supporting disease‐modifying treatments for Parkinson's disease (PD). At the forefront of this development is thermoablation using high‐intensity focused ultrasound, an incisionless treatment that has been extensively tested in ...
Rikke Hahn Kofoed, Victor Schwartz Hvingelby, Jose A. Pineda‐Pardo, Javier Blesa, Steffen Paschen, Anurag Tandon, Juho Joutsa, Andreas Nørgaard Glud   +7 more
wiley   +1 more source